Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation

Young Dae Kim, Kyung Yul Lee, Hyo Suk Nam, Sang Won Han, Jong Yun Lee, Han-Jin Cho, Gyu Sik Kim, Seo Hyun Kim, Myoong-Jin Cha, Seong Hwan Ahn, Seung-Hun Oh, Kee Ook Lee, Yo Han Jung, Hye-Yeon Choi, Sang-Don Han, Hye Sun Lee, Chung Mo Nam, Eun Hye Kim, Ki Jeong Lee, Dongbeom Song, Hui-Nam Park, and Ji Hoe Heo

1Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul; 2Department of Neurology, Gangnam Severance Hospital, Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul; 3Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul; 4Department of Neurology, National Medical Center, Seoul; 5Department of Neurology, Pusan National University Hospital, Pusan National University College of Medicine and Biomedical Research Institute, Busan; 6Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang; 7Department of Neurology, Yonsei University Wonju College of Medicine, Wonju; 8Department of Neurology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon; 9Department of Neurology, Chosun University School of Medicine, Gwangju; 10Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam; 11Department of Neurology, Konyang University College of Medicine, Daejeon; 12Department of Neurology, CHA University Hospital, Hospital, Changwon; 13Department of Neurology, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul; 14Department of Neurology, School of Medicine, Konkuk University, Chungju; Departments of 15Biostatistics, 16Preventive Medicine, and 17Cardiology, Yonsei University College of Medicine, Seoul, Korea.

Received: April 11, 2014
Revised: June 13, 2014
Accepted: July 10, 2014
Corresponding author: Dr. Ji Hoe Heo, Department of Neurology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
Tel: 82-2-2228-1605, Fax: 82-2-393-0705
E-mail: jhheo@yuhs.ac

Purpose: In this study, we investigated the stroke mechanism and the factors associated with ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF) who were on optimal oral anticoagulation with warfarin. Materials and Methods: This was a multicenter case-control study. The cases were consecutive patients with NVAF who developed cerebral infarction or transient ischemic attack (TIA) while on warfarin therapy with an international normalized ratio (INR) ≥2 between January 2007 and December 2011. The controls were patients with NVAF without ischemic stroke who were on warfarin therapy for more than 1 year with a mean INR ≥2 during the same time period. We also determined etiologic mechanisms of stroke in cases. Results: Among 3569 consecutive patients with cerebral infarction or TIA who had NVAF, 55 (1.5%) patients had INR ≥2 at admission. The most common stroke mechanism was cardioembolism (76.0%). Multivariate analysis demonstrated that smoking and history of previous ischemic stroke were independently associated with cases. High CHADS2 score (≥3) or CHA2DS2-VASc score (≥5), in particular, with previous ischemic stroke along with ≥1 point of other components of CHADS2 score or ≥3 points of other components of CHA2DS2-VASc score was a significant predictor for development of ischemic stroke. Conclusion: NVAF patients with high CHADS2/CHA2DS2-VASc scores and a previous ischemic stroke or smoking history are at high risk of stroke despite optimal warfarin treatment. Some other measures to reduce the risk of stroke would be necessary in those specific groups of patients.

Key Words: Cardiac embolism, cerebral infarction, risk factors, atrial fibrillation, anticoagulation
INTRODUCTION

Nonvalvular atrial fibrillation (NVAF) is the most common cause of cardioembolic stroke.\(^1,^2\) Warfarin (vitamin K antagonist) treatment with optimum intensity has been a standard treatment to prevent ischemic stroke or systemic embolism in patients with NVAF.\(^3,^5\)

However, despite having a therapeutic intensity of oral anticoagulation (OAC) therapy, some patients still suffer from ischemic stroke.\(^6\) Some patients may have a hypercoagulable state, and subsequently intractable to appropriate OAC therapy.\(^7,^8\) Furthermore, noncardioembolic stroke such as atherothrombotic stroke or lacunar infarction can occur in patients with NVAF,\(^9,^10\) and these types of ischemic stroke may not be successfully prevented with OAC. Until now, however, there has been limited information regarding the clinical determinants for development of ischemic stroke and the stroke mechanism in patients with NVAF who were on warfarin therapy in real clinical setting.

In this study, we investigated which factors are associated with the development of ischemic stroke in patients with NVAF who are on optimal OAC therapy. We also determined the etiologic mechanisms of stroke in them.

MATERIALS AND METHODS

Study population

This study was a multicenter, case-control study with prospective case ascertainment and retrospective data collection between January 2007 and December 2011. Cases and controls were collected from total 14 hospitals in South Korea. This study was approved by the Institutional Review Board at each participating hospital and the requirement for informed consent was waived.

Consecutive patients with cerebral infarction or transient ischemic attack (TIA) who were admitted to study hospitals during study period were investigated for eligibility for this study. All patients underwent brain CT/MRI, or both. During admission, demographic data, medical history, vascular risk factors, and clinical manifestations were collected for each patient. Among patients with cerebral infarction or TIA, a patient was eligible as the cases if they had NVAF with prior warfarin therapy and their international normalized ratio (INR) was $\geq 2$ at presentation of ischemic stroke or TIA.

Controls were selected from patients who were treated in the department of neurology or cardiology at each study hospital during the same time period. We reviewed the medical records and results of laboratory tests. Patients were included as controls when they had NVAF and received warfarin for more than 1 year with a mean INR $\geq 2$. Controls should not have a cerebral infarction or TIA for one year while they had been on warfarin therapy with their mean INR $\geq 2$. Controls were matched 1:1 to cases on age and gender.

Clinical variables

We collected data for demographics, vascular risk factors, underlying cardiovascular diseases, and concurrent medications in cases and controls. Atrial fibrillation (AF) was categorized as paroxysmal or persistent/permanent AF. The CHADS\(^2\) score or CHA\(^2\)DS\(-V\)ASc scores were calculated for all patients. The index cerebral infarction or TIA was not considered for calculating the CHADS\(^2\) score or CHA\(^2\)DS\(-V\)ASc score. Concomitant potential cardiac sources of embolism was defined as having at least one of left atrial/atrial appendage thrombus, sick sinus syndrome, recent myocardial infarction ($<4$ weeks), left ventricular thrombus, dilated cardiomyopathy, and akinetic left ventricular segment, along with NVAF. Patients were regarded as smokers if they smoked within the 3 months period prior to admission. INR data were also collected; the INR at admission for cases and the mean INR during the 1 year prior to enrollment for controls were used in the analysis. We also calculated time in therapeutic range by the method of Rosendaal, et al.\(^11\) among the patients enrolled as controls (mean number of checking INR=6). However, we could not calculate time in therapeutic range in cases because all patients included in the case group had not followed up before index stroke at each hospital.

We collected data of location of ischemic lesions and the initial stroke severity assessed by the National Institute of Health Stroke Scale in cases. In patients with cerebral infarction, we determined the stroke mechanism, which was based on the Trial of Org 10172 in Acute Stroke Treatment classification.\(^12\) Two neurologists (YDK and HSN) independently reviewed brain imaging including the diffusion weighted images and angiographic studies. If the classification was conflicting, consensus was reached through the discussion together with the third investigator (KYL).

Statistical analyses

Statistical analysis was performed using the Windows SPSS package (version 18.0, SPSS Inc., Chicago, IL, USA) and
the SAS package (version 9.1.3, SAS Inc., Cary, NC, USA). Fisher’s exact chi-square test was used for categorical variables and independent t-test or Kruskal-Wallis test for continuous variables, as appropriate. In the investigation of determinants for cerebral infarction or TIA on therapeutic warfarin treatment between the case and control group, categorical variables were compared with McNemar test or exact McNemar test and continuous variables with paired t-tests or Wilcoxon signed-rank test, as appropriate. To find independent factors that were associated with development of cerebral infarction or TIA while on optimal warfarin therapy, a conditional logistic regression analysis was performed using variables with \( p < 0.05 \) on univariate analysis. Statistical significance was set at \( p < 0.05 \).

**RESULTS**

**Characteristics of cases with ischemic stroke**

During the study period, a total of 25415 consecutive patients with cerebral infarction or TIA were admitted to study hospitals. Among them, after exclusion of patients without NVAF, those without previous OAC therapy, and those whose INR was <2, 55 patients (50 patients with cerebral infarction and 5 patients with TIA) were included in this study as cases (Fig. 1). The location of cerebral infarction was most common in the middle cerebral artery territory (35/50, 70.0%), followed by multiple arterial territories (9/50, 18.0%), brainstem (5/50, 10.0%), and posterior cerebral artery territory (1/50, 2.0%). Among 50 cases with cerebral infarction, their median National Institutes of Health Stroke Scale (NIHSS) score at admission was 3 [interquartile range (IQR) 1–11].

**Stroke mechanism and clinical outcomes**

Among 55 patients included in the case group, we could determine the stroke mechanism in 50 patients because 5 patients had no ischemic lesion on diffusion weighted imaging. Among cases with cerebral infarction (n=50), diffusion weighted MRI was performed in 48 patients (96.0%) and angiographic studies were done in 49 patients (98.0%). Of them, 38 patients (76.0%) were classified as cardioembolic stroke and 12 patients (24.0%) as stroke of undetermined etiology due to multiple causes [cardioembolism (CE)+large artery atherosclerosis in 9 patients (18.0%) and CE+lacunar infarction in 3 patients (6.0%)]. In comparison of baseline characteristics between groups according to stroke mechanism, CE was significantly associated with the presence of congestive heart failure, while there were no differences in the age, gender, risk factors, and previous medication before index stroke (Table 1). Neurologic deficits at admission was more severe in CE (median NIHSS score at admission 4, IQR 2–15) compared to those in CE+large artery atherosclerosis (median 1, IQR 0‒3) or CE+lacunar infarction (median 1, IQR 0.5–1.5) \((p=0.022)\).

**Determinants of ischemic events despite therapeutic oral anticoagulation**

The comparison between cases and controls is shown in Table 2. Cases were more likely to be smokers, and more frequently had a history of previous ischemic stroke or TIA. The CHADS\(_2\) score or CHA\(_2\)DS\(_2\)-VASc score was higher in cases than in controls \((p<0.001\) at each comparison). Other baseline characteristics were comparable between two groups. Median time in therapeutic range in control group was 64.2% (IQR 49.2‒81.8%).

Multivariate analysis showed that smoking and history of previous ischemic stroke were independently associated with the occurrence of cerebral infarction or TIA (Table 3). Cases with CHADS\(_2\) score \(\geq 3\) or CHA\(_2\)DS\(_2\)-VASc score \(\geq 5\) had significantly higher odds ratio of having cerebral infarction or TIA than patients with a CHADS\(_2\) score or CHA\(_2\)DS\(_2\)-VASc score of 0–1 (Table 3).

The previous ischemic stroke or TIA, which contributed two points to the CHADS\(_2\)/CHA\(_2\)DS\(_2\)-VASc score, was a
Despite optimal warfarin treatment, cerebral infarction or TIA can occur in patients with NVAF. Among patients with NVAF who received warfarin in large contemporary randomized controlled trials, the rate of stroke or non-central nervous system embolism was 1.2% to 2.3% per year. In our study, of 683 ischemic stroke or TIA patients with known NVAF and OAC therapy, 8.1% (n=55) had INR ≥2.0, which is similar to that [7.9% (44/556)] in Fukoka Stroke Registry. Occurrence of stroke in patients with NVAF who are on warfarin with therapeutic intensity may be ascribed to other causes such as atherosclerosis and lacunar infarction. Cerebral artery atherosclerosis co-exists in 20‒50% of patients with NVAF and may develop stroke. Likewise, lacunar infarction may develop in patients with NVAF. However, our results demonstrated that most ischemic strokes (76%) during OAC developed due to CE.

Considering positive association between risk stratification
Our findings suggest that warfarin treatment with INR 2.0–3.0 may be insufficient to effectively prevent stroke in patients with higher CHADS\(_2\) score (≥3) or CHA\(_2\)DS\(_2\)-VASc score (≥5) with a previous stroke or TIA. In these patients, more potent antithrombotic measures can be considered. Current guidelines mention that it may be reasonable to raise the intensity of warfarin to a maximum target INR of 3.0–3.5, rather than add an antiplatelet agent in patients with AF who sustain ischemic stroke or systemic embolism during warfarin treatment with INR 2.0–3.0.\(^\text{17}\) However, meta-analysis showed that new oral anticoagulants (NOACs) seemed to be associated with a significant reduction (relative

### Table 2. Comparison of Baseline Characteristics between Cases and Controls

|                                | Control (n=55) | Case (n=55) | \(p\) value |
|--------------------------------|---------------|-------------|-------------|
| **Age**                        | 72±7.1        | 72±7.2      | 1           |
| **Male sex**                   | 32 (58.2)     | 32 (58.2)   | 1           |
| **Permanent atrial fibrillation** | 40 (72.7)    | 41 (74.5)   | 1           |
| **Concomitant PCSE**           | 6 (10.9)      | 8 (14.5)    | 0.774       |
| **Congestive heart failure**   | 26 (47.3)     | 23 (41.8)   | 0.710       |
| **Hypertension**               | 40 (72.7)     | 48 (87.3)   | 0.077       |
| **Diabetes**                   | 25 (45.5)     | 23 (41.8)   | 0.839       |
| **Hyperlipidemia**             | 15 (27.3)     | 12 (21.8)   | 0.648       |
| **Smoking**                    | 3 (5.5)       | 18 (32.7)   | 0.001       |
| **Previous ischemic stroke**   | 5 (9.1)       | 34 (61.8)   | <0.001      |
| **Previous ischemic heart disease** | 6 (10.9)   | 12 (21.8)   | 0.210       |
| **Peripheral arterial occlusive diseases** | 1 (1.8) | 6 (10.9)   | 0.125       |
| **Prior medication**           |               |             |             |
| Antiplatelet                   | 16 (29.1)     | 25 (45.5)   | 0.137       |
| Statin                         | 20 (36.4)     | 26 (47.3)   | 0.345       |
| ACE I                          | 29 (52.7)     | 32 (58.2)   | 0.700       |
| Antiarrhythmic agents          | 34 (61.8)     | 31 (56.4)   | 0.700       |
| **International normalized ratio** | 2.4 (2.2–2.7) | 2.6 (2.2–3.1) | 0.077      |
| **CHADS\(_2\) score**         |               |             | <0.001      |
| 0                              | 3 (5.5)       | 1 (1.8)     |             |
| 1                              | 11 (20.0)     | 2 (3.6)     |             |
| 2                              | 19 (34.5)     | 8 (14.5)    |             |
| 3                              | 16 (29.1)     | 24 (43.6)   |             |
| 4                              | 5 (9.1)       | 8 (14.5)    |             |
| 5                              | 1 (1.8)       | 11 (20.0)   |             |
| 6                              | 0 (0.0)       | 1 (1.8)     |             |
| **CHA\(_2\)DS\(_2\)-VASc score** |             |             | <0.001      |
| 1                              | 4 (7.3)       | 2 (3.6)     |             |
| 2                              | 9 (16.4)      | 0 (0.0)     |             |
| 3                              | 11 (20.0)     | 4 (7.3)     |             |
| 4                              | 16 (29.1)     | 13 (23.6)   |             |
| 5                              | 9 (16.4)      | 17 (30.9)   |             |
| 6                              | 5 (9.1)       | 9 (16.4)    |             |
| 7                              | 1 (1.8)       | 10 (18.2)   |             |

PCSE, potential cardiac sources of embolism; ACE I, angiotensin converting enzyme inhibitor.
Data are presented as mean (standard deviation) or number (percentages).

It was expected that higher CHADS\(_2\) scores or CHA\(_2\)DS\(_2\)-VASc scores were associated with a higher risk of stroke or TIA during warfarin treatment. However, even though the CHADS\(_2\) score or CHA\(_2\)DS\(_2\)-VASc score was same, the risk of stroke was substantially different according to the presence of previous stroke or TIA. Although the scores on the risk stratification were similarly high (CHADS\(_2\) ≥3 or CHA\(_2\)DS\(_2\)-VASc ≥5), the risk for ischemic stroke was 3.81 times (CHADS\(_2\) ≥3) and 3 times (CHA\(_2\)DS\(_2\)-VASc ≥5) higher in patients with a history of previous stroke or TIA than in those without history of previous stroke or TIA.
risk reduction 14%) in rates of stroke or systemic embolism in patients with previous stroke or TIA, compared to warfarin treatment. Because stroke rate during OAC was reported to be higher in Asians than non-Asians and NOAC seems to be more effective than warfarin in Asians than non-Asians, NOAC may have some advantage of treating this specific group. Recently, local therapy of left atrial appendage closure with Watchman device showed some potential as alternatives of OAC. New trials targeting this particular group of patients would be necessary to determine which treatment strategy is beneficial in them.

In this study, smoking was independently associated with the risk of cerebral infarction or TIA. However, previous studies have not consistently shown positive relationship between smoking and the risks of stroke in patients with NVAF. Intracardiac thrombus formation in NVAF is affected by endocardial damage, inflammation, and platelet activation as well as blood stasis in the left atrium. Smoking can inhibit secretion of endogenous tissue plasminogen activator, increase the plasminogen activator inhibitor-1 activity, induce systemic inflammation, activate platelets, and damage endothelial cells, which may subsequently lead to a hypercoagulable state. Smoking is a modifiable risk factor. Our results suggest that cessation of smoking is essential to further reduce stroke risks in patients with NVAF who are treated with OAC.

There are some limitations of our study. Although this study was a multicenter case-control study, the data were collected retrospectively. Second, we could not investigate the effect of age and gender due to the study design that matched age and gender between cases and controls. Third, because this study was a retrospective cross-sectional design, our results cannot prove a causal relationship between high CHADS2/CHA2DS2-VASc scores and a previous isch-

### Table 3. Conditional Logistic Regression Analysis for Ischemic Strokes and TIA

|                        | Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value |
|------------------------|--------------------|---------|--------------------|---------|--------------------|---------|
| Smoking                | 6.349 (1.152‒34.997) | 0.034   | 8.477 (1.472‒48.833) | 0.017   | 10.467 (1.248‒87.817) | 0.030   |
| Previous ischemic stroke | 7.198 (2.393–21.650) | <0.001  |                   |         |                   |         |
| CHADS2 score           |                    |         |                    |         |                    |         |
| 0–1                   |                   |         | 1                  |         |                   |         |
| 2                     |                   |         | 1.650 (0.289–9.434) | 0.573  |                   |         |
| 3                     |                   |         | 12.677 (1.731–92.832) | 0.012  |                   |         |
| 4                     |                   |         | 7.947 (1.102–57.301) | 0.040  |                   |         |
| ≥5                    |                   |         | 53.434 (3.482–820.101) | 0.004  |                   |         |
| CHA2DS2-VASc score     |                    |         |                    |         |                    |         |
| 0–1                   |                   |         | 1                  |         |                   |         |
| 2                     |                   |         | 5.692 (0.223–145.442) | 0.293  |                   |         |
| 3                     |                   |         | 7.749 (0.438–137.126) | 0.163  |                   |         |
| ≥5                    |                   |         | 46.232 (2.069–1033.111) | 0.016  |                   |         |

NA, not applicable; CI, confidence interval; TIA, transient ischemic attack.

### Table 4. Conditional Logistic Regression Analysis According to the Presence of Previous Strokes or TIA

|                        | Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value |
|------------------------|--------------------|---------|--------------------|---------|
| Smoking                | 8.084 (1.95–54.709) | 0.032   | 8.329 (1.069–64.905) | 0.043   |
| According to CHADS2 score component |      |         |                    |         |
| 0–2 without previous ischemic stroke | 1      |         |                    |         |
| ≥3 without previous ischemic stroke       | 3.853 (0.857–17.323) | 0.079  |                   |         |
| 2 with previous ischemic stroke         | 3.832 (0.116–126.306) | 0.451  |                   |         |
| ≥3 with previous ischemic stroke       | 14.682 (3.492–61.723) | <0.001 |                   |         |
| According to CHA2DS2-VASc score component |      |         |                    |         |
| 0–4 without previous ischemic stroke | -      |         | 1                  |         |
| ≥5 without previous ischemic stroke | -      |         | 9.336 (1.412–61.741) | 0.020  |
| 2–4 with previous ischemic stroke       | -      |         | 12.193 (1.562–95.139) | 0.017  |
| ≥5 with previous ischemic stroke       | -      |         | 27.914 (4.138–188.304) | 0.001  |

TIA, transient ischemic attack; CI, confidence interval.
emic stroke or smoking and stroke risk. Moreover, the control group was selected if patients had no stroke before 1 year during OAC, and the sample size of our study was small and there is a potential for selection bias, hence the results cannot be generalized.

For calculation of CHADS\(_2\): scores and CHA\(_2\)DS\(_2\)-VASC scores, 2 points are given to NVAF patients with a history of stroke TIA, and oral anticoagulation use is recommended in them. However, we showed that patients with a stroke TIA are at very high risk of recurrent stroke despite warfarin treatment as is recommended, particularly if their CHADS\(_2\): scores are ≥3 or CHA\(_2\)DS\(_2\)-VASC scores are ≥5. Our findings suggest that some other measures to reduce the risk of stroke should be determined in the future in those specific groups of patients.

**ACKNOWLEDGEMENTS**

This work was supported by a grant of the Korea Healthcare Technology R&D Project through the Korean Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI10C2020).

**REFERENCES**

1. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 1986;43:71-84.
2. Han SW, Nam HS, Kim SH, Lee JY, Lee KY, Heo JH. Frequency and significance of cardiac sources of embolism in the TOAST classification. Cerebrovasc Dis 2007;24:463-8.
3. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57:223-42.
4. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:227-76.
5. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457-507.
6. Paciaroni M, Agnelli G, Ageno W, Caso V, Corea F, Lanari A, et al. Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis 2010;212:564-6.
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
8. Lip GY, Nieuwaal R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
9. Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, et al. Increases in cerebral atherosclerosis according to CHADS\(_2\) scores in patients with stroke with nonvalvular atrial fibrillation. Stroke 2011;42:930-4.
10. Melkas S, Putaala J, Oksala NK, Pohjasvuara T, Oksala A, Kaste M, et al. Small- vessel disease relates to poor poststroke survival in a 12-year follow-up. Neurology 2011;76:734-9.
11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.
12. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
13. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med 2012;172:623-31.
14. Nakamura A, Ago T, Kamouchi M, Hata J, Matsuo R, Kuroda J, et al. Intensity of anticoagulation and clinical outcomes in acute cardioembolic stroke: the Fukuoka Stroke Registry. Stroke 2013; 44:3239-42.
15. Kanter MC, Tegeler CH, Pearce LA, Weinberger J, Feinberg WM, Anderson DC, et al. Carotid stenosis in patients with atrial fibrillation. Prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Intern Med 1994;154:1372-7.
16. Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke 2001;32:2828-32.
17. Fuster V, Rydén LE, Cannon DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:e269-367.
18. Tuomas G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012;43:3298-304.
19. Alberts EM, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta- analysis. Stroke 2013;44:1329-36.
20. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014;111:789-97.
21. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720-9.
22. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;41:2731-8.
23. Novello P, Ajmar G, Bianchini D, Bo GP, Cammarata S, Firpo MP, et al. Ischemic stroke and atrial fibrillation. A clinical study. Ital J Neurol Sci 1993;14:571-6.
24. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
25. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009;373:155-66.
26. Johnson CM, Mureebe L, Silver D. Hypercoagulable states: a review. Vasc Endovascular Surg 2005;39:123-33.
27. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997;17:2167-76.
28. Oh SM, Stefani KM, Kim HC. Development and application of chronic disease risk prediction models. Yonsei Med J 2014;55:853-60.